Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

(2021) Eric P Winer et al.   LANCET ONCOLOGY

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

(2021) Isak W. Tengesdal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression

(2021) Isak W. Tengesdal et al.   Frontiers in Immunology

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

(2020) Caroline Bergenfelz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

(2020) Andrew M. K. Law et al.   Cells

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

(2020) Balamayoora Theivanthiran et al.   JOURNAL OF CLINICAL INVESTIGATION

NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway

(2020) Qiao Zheng et al.   BIOSCIENCE REPORTS

PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer

(2020) Wendan Yu et al.   Cell Death & Disease

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

(2019) Alexander Thiem et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

PD‑L1 expression levels on tumor cells affect their immunosuppressive activity

(2019) Yang Zheng et al.   Oncology Letters

NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis

(2019) Nour Ershaid et al.   Nature Communications

Mechanisms regulating PD-L1 expression on tumor and immune cells

(2019) Shuming Chen et al.   Journal for ImmunoTherapy of Cancer

IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer

(2018) Te-Chia Wu et al.   CANCER RESEARCH

OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation

(2018) Carlo Marchetti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

(2018) Jiawen Qian et al.   Journal of Neuroinflammation

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation

(2018) Irena Kaplanov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression of checkpoint molecules on myeloid-derived suppressor cells

(2017) Marlene Ballbach et al.   IMMUNOLOGY LETTERS

The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma

(2017) Xiaodong Feng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer

(2017) Kenji Gonda et al.   Oncology Letters

P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer

(2017) Ju Young Bae et al.   Oncotarget

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer

(2015) Jiahuai Wen et al.   MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity

(2014) Y. Cao et al.   CANCER RESEARCH

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche

(2012) Jaclyn Sceneay et al.   OncoImmunology

IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function

(2010) Moshe Elkabets et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interleukin-1β promotes the expression of monocyte chemoattractant protein-1 in human aorta smooth muscle cells via multiple signaling pathways

(2009) Jun Hee Lim et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β

(2009) Miyako Okamoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY